Breaking News

The AMR Action Fund Invests in BioVersys in Fight Against Drug-Resistant Bacteria

Deal aims to advance its mission of enabling the launch of two to four antimicrobials by 2030.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The AMR Action Fund, a public-private partnership investing in biotech companies developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund’s first investment in Europe and is an important step toward building an international portfolio of companies that are developing urgently needed antimicrobials.   Drug-resistant bacterial infections were associated with nearly 5 million deaths in 2019. BioVersys&#8217...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters